Inventiva S.A. ADR (IVA) Stock Price, Quote & News

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 80 44 75 00

Website: inventivapharma.com

Address:

50 rue de Dijon, Daix, France

Quantumup Sep. 12 at 10:32 AM

Canaccord Genuity⬆️the PT on $MDGL to $526 from $428, reiterated, at a Buy rating and said, while the #MASH drug development competitive landscape remains crowded, we believe Madrigal's strong efficacy and safety profile, coupled with being an oral drug, allows for it to remain competitive for the foreseeable future. We currently model peak revenue for Rezdiffra in 2032 with US revenue of $5.1B and EU revenue of $678M. To be conservative, we assume Rezdiffra pricing to drop in 2033 by 25% as part of IRA negotiations. We remain bullish on shares of $MDGL and would be strong buyers going into the EU launch and continued U.S. growth. $NVO $IVA $VKTX $ALGS

0 · Reply

Quantumup Sep. 4 at 4:21 PM

H.C. Wainwright assumed coverage of $MDGL at a Buy rating and a $500 price target. $NVO $IVA LLY $VKTX $ALGS AKRO ETNB SGMT H.C. Wainwright said: A #MASH foundation set for sustainable market leadership. H.C. Wainwright went on to say:

0 · Reply

JarvisFlow Sep. 2 at 12:00 PM

Guggenheim updates rating for Inventiva ( $IVA ) to Buy, target set at 9 → 13.

0 · Reply

StockScanners Aug. 29 at 4:25 AM

$IVA keep watch if this holds above 5.90

0 · Reply

History101 Aug. 28 at 7:55 PM

$IVA 476 watching 8/28/2025

0 · Reply

BioRich Aug. 28 at 6:17 PM

$ALT Should have listened... $IVA continues to charge ahead while $ALT sits red. Know what you own.

0 · Reply

BigSqueezeComing Aug. 28 at 9:24 AM

$IVA gappers

0 · Reply

DARKP00L Aug. 27 at 1:21 PM

$IVA 09:17 on Aug. 27 2025 Piper Sandler Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $26 #tradeideas

0 · Reply

topstockalerts Aug. 27 at 1:03 PM

Pre Market Top Gainers PT2 $FLNT $MBRX $KSS $EBON $IVA

0 · Reply

Quantumup Aug. 27 at 11:40 AM

Piper Sandler🏁 $IVA OW/$26: We are initiating coverage on Inventiva with an OW rating and $26 PT as the company is developing its lead asset, lanifibranor (oral pan-PPAR agonist), in #MASH with Ph3 NATiV3 topline in 2H26. Recognize, $IVA is trading at a market cap of ~$650M, representing a 14x valuation gap vs $MDGL ($9.2B) in MASH, which we believe provides a lucrative buying opportunity given $IVA has an oral asset de-risked for PoS. Thus, considering REZDIFFRA's successful launch progress so far in MASH, this highlights the high unmet needs, where lanifibranor has especially attractive positioning for #T2D MASH patients given its unique benefits to glycemic control/insulin resistance (~10.6M F2-3 US MASH patients estimated by 2030, with ~15-20% T2D co-morbidity rate). Ultimately, we believe Ph3 NATiV3 in 2H26 is de-risked and could be a key stock-moving event to further highlight lanifibranor's compelling MASH value proposition and drive share gains. $NVO $LLY $VKTX ALGS ALT AKRO ETNB

0 · Reply

Inventiva to Participate in Upcoming September Investor Conferences

Aug 11, 2025, 4:00 PM EDT - 4 weeks ago

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 4:00 PM EDT - 6 weeks ago

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Jul 9, 2025, 4:05 PM EDT - 2 months ago

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Jul 7, 2025, 4:00 PM EDT - 2 months ago

Inventiva receives $10 million milestone payment from CTTQ

Jul 2, 2025, 4:00 PM EDT - 2 months ago

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

May 27, 2025, 4:00 PM EDT - 3 months ago

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

May 23, 2025, 2:30 AM EDT - 4 months ago

Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:00 AM EDT - 4 months ago

Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025

May 5, 2025, 2:30 AM EDT - 4 months ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Apr 30, 2025, 4:00 PM EDT - 4 months ago

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Apr 24, 2025, 4:01 PM EDT - 5 months ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Apr 15, 2025, 4:00 PM EDT - 5 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Apr 1, 2025, 5:00 PM EDT - 5 months ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Mar 27, 2025, 10:50 AM EDT - 6 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:00 PM EDT - 6 months ago

Inventiva reports its 2024 full year results and provides a business update

Mar 19, 2025, 4:00 PM EDT - 6 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Feb 26, 2025, 4:00 PM EST - 7 months ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Feb 20, 2025, 4:00 PM EST - 7 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Feb 10, 2025, 4:00 PM EST - 7 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Jan 29, 2025, 4:00 PM EST - 8 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Jan 22, 2025, 4:00 PM EST - 8 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Dec 17, 2024, 4:00 PM EST - 9 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 2:30 AM EST - 9 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Dec 12, 2024, 4:00 PM EST - 9 months ago

Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024

Nov 21, 2024, 4:00 PM EST - 10 months ago

Inventiva reports 2024 Third Quarter Financial Information¹

Nov 20, 2024, 4:00 PM EST - 10 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Nov 18, 2024, 8:30 AM EST - 10 months ago

Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams

ALIT

Nov 15, 2024, 4:00 PM EST - 10 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Oct 30, 2024, 4:00 PM EDT - 11 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Oct 21, 2024, 8:30 AM EDT - 11 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Oct 14, 2024, 1:45 PM EDT - 11 months ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Oct 14, 2024, 10:48 AM EDT - 11 months ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Oct 14, 2024, 2:35 AM EDT - 11 months ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Oct 14, 2024, 2:30 AM EDT - 11 months ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Jul 31, 2024, 4:00 PM EDT - 1 year ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Jul 18, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces a €20.1 million issuance of royalty certificates

Jul 8, 2024, 2:36 PM EDT - 1 year ago

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Jul 5, 2024, 4:00 PM EDT - 1 year ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Jun 21, 2024, 4:00 PM EDT - 1 year ago

Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024

May 30, 2024, 2:30 AM EDT - 1 year ago

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

May 22, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

May 21, 2024, 4:00 PM EDT - 1 year ago

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

May 16, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

May 13, 2024, 2:30 AM EDT - 1 year ago

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Apr 3, 2024, 4:00 PM EDT - 1 year ago

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Mar 28, 2024, 11:27 AM EDT - 1 year ago

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 3:00 AM EDT - 1 year ago

Inventiva announces the nomination of Andre Turenne as Director

Quantumup Sep. 12 at 10:32 AM

0 · Reply

Quantumup Sep. 4 at 4:21 PM

0 · Reply

JarvisFlow Sep. 2 at 12:00 PM

Guggenheim updates rating for Inventiva ( $IVA ) to Buy, target set at 9 → 13.

0 · Reply

StockScanners Aug. 29 at 4:25 AM

$IVA keep watch if this holds above 5.90

0 · Reply

History101 Aug. 28 at 7:55 PM

$IVA 476 watching 8/28/2025

0 · Reply

BioRich Aug. 28 at 6:17 PM

$ALT Should have listened... $IVA continues to charge ahead while $ALT sits red. Know what you own.

0 · Reply

BigSqueezeComing Aug. 28 at 9:24 AM

$IVA gappers

0 · Reply

DARKP00L Aug. 27 at 1:21 PM

$IVA 09:17 on Aug. 27 2025 Piper Sandler Initiates Coverage On Inventiva with Overweight Rating, Announces Price Target of $26 #tradeideas

0 · Reply

topstockalerts Aug. 27 at 1:03 PM

Pre Market Top Gainers PT2 $FLNT $MBRX $KSS $EBON $IVA

0 · Reply

Quantumup Aug. 27 at 11:40 AM

0 · Reply

Quantumup Aug. 20 at 11:48 AM

Citizens⬆️ $MDGL $485 from $483/reit Mkt OP: We are pleased with Rezdiffra's EU approval with the company planning its launch in Germany next quarter. Similar to its U.S. launch, $MDGL will target ~370K EU patients diagnosed with F2/ F3 MASH and under the care of a liver specialist. Full approval in both geographies is contingent on the success in the ongoing 54-month outcomes portion of the MAESTRO-NASH or MAESTRO-NASH OUTCOMES trials in well-compensated NASH cirrhosis. Recall that success in the MAESTRO-NASH OUTCOMES trial could expand Rezdiffra to treat compensated #MASH cirrhosis and potentially double its market opportunity. $MDGL told us it will disclose pricing details closer to launch while we assume a $20K annual price (vs. $49K in the U.S.). Importantly, the EU guidelines already list Rezdiffra as a first-line therapy for #MASH, positioning it well for a strong early launch overseas. We have raised our EU POS to 100% (from 90%) and model ~$2B in peak EU sales. $NVO $IVA $LLY $VKTX

0 · Reply

Quantumup Aug. 18 at 3:30 PM

Goldman Sachs reiterated $MDGL Buy/$567. ~sees Rezdiffra as likely to sustain meaningful mkt shr ~ $NVO could expand addressable pt pop ~sees cont's growth opps for $MDGL $NVO $IVA $LLY $VKTX AKRO ALGS ETNB SGMT #MASH Goldman Sachs said in its note to investors:

0 · Reply

Quantumup Aug. 13 at 11:49 AM

Piper Sandler y'day reiterated $MDGL Overweight/$400. & Jefferies (also A/O)⬆️ $MDGL PT to $502 from $411 and reiterated at a Buy. $IVA $AKRO $VKTX $ALGS ETNB SGMT NVO LLY #MASH Piper Sandler and Jefferies said:

0 · Reply

Quantumup Aug. 6 at 2:38 PM

Morgan Stanley reiterated $AKRO Overweight-$84 and said, "Zalfermin discontinuation in #MASH leaves EFX in strong competitive position." $NVO $LLY $IVA $ETNB VKTX ALGS SGMT Morgan Stanley went on to say:

0 · Reply

Quantumup Aug. 6 at 11:43 AM

Goldman Sachs y'day reiterated $MDGL Buy/$567. $NVO $LLY $IVA $AKRO VKTX ALGS ETNB SGMT Goldman Sachs said:

1 · Reply

Quantumup Aug. 4 at 10:51 AM

TD Cowen🏁 $AKRO Buy/$76—Says EFX has differentiated clinical profile—Ph3 trial=high PoS—models peak U.S. sales=$2.85B/$4.85B in F3/F4. $MDGL $IVA $ETNB $VKTX ALGS LLY NVO #MASH TD Cowen said, "We are initiating on $AKRO with a Buy, $76 target. $AKRO's efruxifermin, an FGF21 analog, has a differentiated clinical profile, backed by strong efficacy data, that could drive commercial success focused in F3 and F4 MASH. EFX is in Ph3 trials with high probabilities of success; topline data for the Ph3 SYNCHRONY F2/F3 MASH trial is due 1H27. We model peak US sales of $2.85B/$4.85B in F3/F4 MASH."

0 · Reply

TaxiBiotech_ Jul. 30 at 2:03 PM

🧵 1/ The first Q2/H1 2025 earnings from the BIOTECH 🧬 sector are out. Several European players lead the way, but a few US names are in the mix too. 💡For investors: Here’s a breakdown of revenue, cash, runway & upcoming clinical milestones. Let’s go 👇 DBV Technologies $DBVT 🇫🇷 • Q2 revenue: $1.47M • Cash: $103.2M (up from $32.5M in 2024) • Net loss Q2: –$41.9M • Higher R&D spend driven by COMFORT Toddlers trial Inventiva $IVA 🇫🇷 • H1 revenue: €4.5M (vs €0M in 2024) • H1 OpEx: €53.9M. R&D flat at €45.2M • Cash: €122M – runway into Q3 2026 📌 Preparing for key milestones but will need additional funding Idorsia $IDIA 🇨🇭 • H1 revenue: CHF 131M • Cash runway: into end‑2026 • QUVIVIQ (insomnia) drives sales: +145% YoY 🔜 Approaching profitability by late 2027 Galapagos $GLPG 🇧🇪 • H1 revenue: €140M (flat YoY) • H1 net loss: –€259M • Cash: €3.09B 🔁 Major restructuring underway: Innovative unit spin-off & 40% workforce cut

0 · Reply

Quantumup Jul. 22 at 12:10 PM

Citizens reiterated $MDGL Mkt OP/$470 after its 2Q25 survey showed a 46% prescription rate for Rezdiffra (up from 42% in its 1Q survey)" $IVA $AKRO $ALGS $VKTX ETNB SGMT LLY #MASH Citizens in its note to investors said, "Our 2Q25 survey shows a 46% prescription rate for Rezdiffra (up from 42% in our 1Q survey), with ~60% of patients on paid drug and consistent high persistence; we reiterate our Market Outperform rating and $470 risk-adjusted, DCF-derived price target on Madrigal Pharmaceuticals. Most metrics in our 2Q25 physician survey improved from 1Q, which is a good sign coming out of the typical 1Q reimbursement dynamics. Citizens additionally said:

0 · Reply

Thestocktraderhubzee Jul. 3 at 10:46 AM

WATCHLIST JUL 03 2025 $REGN Regeneron's Lynozyfic Granted FDA Accelerated Approval For Advanced Multiple Myeloma As First BCMAxCD3 Bispecific Antibody With Extended Dosing Flexibility $ALNY Alnylam Canada Says OXLUMO Is Now Funded Across Canada Through Both Public And Private Plans For Treatment Of PH1 In Pediatric And Adult Patients $UPS UBS Maintains Buy on United Parcel Service, Lowers Price Target to $124 $IVA Inventiva Publishes Phase 2b NATIVE Trial Data In Journal Of Hepatology Reports Showing Lanifibranor Improves Liver Cell Function In MASH And MASLD $AIRE ReAlpha Tech shares are trading higher after the company announced the launch of its AI-powered loan officer assistant.

0 · Reply

BigSqueezeComing Jul. 2 at 8:13 PM

$IVA should go higher..

0 · Reply

BigSqueezeComing Jul. 2 at 8:13 PM

$IVA https://finance.yahoo.com/news/inventiva-announces-publication-journal-hepatology-200000719.html

0 · Reply

Quantumup Jul. 2 at 12:09 PM

Citizens reit $MDGL MKT-OP/470: "Madrigal ( $MDGL, MO, $470 PT) will deliver a podium presentation highlighting a comparative meta-analysis of glucagon receptor agonists vs. Rezdiffra in MASLD and MASH during the "The Evolving Landscape of MASLD: From Pathophysiology to Therapeutic Innovations" session on Saturday, July 12. Rezdiffra will be highlighted in two posters, which will discuss meta-analyses comparing its efficacy to AkeroanIs ( $AKRO, NC) FGF21 efruxifermin, along with a systemic review of Rezdiffra's randomized controlled trials. The U.S. Rezdiffra launch continues to exceed expectations, with >17K patients on drug as of last quarter and sales handily beating consensus (our coverage here). MDGL is also gearing up for its EU launch, with a regulatory decision anticipated in August. Data recently presented at EASL for Rezdiffra and efruxifermin in compensated cirrhotics showed promise (our coverage here), and we look forward to the comparative analysis in MASH." $IVA $VKTX $ALGS

1 · Reply

Market Cap	529.01M
Revenue (ttm)	15.93M
Net Income (ttm)	-199.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,251.35%
Debt to Equity Ratio	-0.51

Volume	128,100
Avg Vol	42,398
Day's Range	N/A - N/A
Shares Out	95.66M
Stochastic %K	51%
Beta	0.69
Analysts	Strong Sell
Price Target	$14.00